Trial Profile

A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC/TDF

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emtricitabine/tenofovir alafenamide (Primary) ; Emtricitabine/tenofovir disoproxil fumarate
Indications HIV-1 infections
Focus Registrational; Therapeutic Use
Acronyms Study 1089; Switch
Sponsors Gilead Sciences

Most Recent Events

16 Mar 2019 This trial has been completed in Belgium, according to European Clinical Trials Database.
07 Mar 2019 Results of a pooled analysis of 7 randomized, double-blind clinical trials assessing the efficacy and safety of TAF vs. TDF for ART initiation or switch in women, presented at the 26th Conference on Retroviruses and Opportunistic Infections
07 Mar 2019 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com